Dr. Swee Lay Thein and Dr. Stuart Orkin won the $3 million Breakthrough Prize in Life Sciences for their work toward a ...

Cancer cells excel at evading detection, but subtle chemical differences set them apart from healthy cells. Now, a team of ...

For the millions of people living with genetic diseases like muscular dystrophy and inherited liver disorders, one of the ...

There are plenty of reasons, though, to be bullish on the stock, not the least of which is its improved cash position. The ...

The latest health news highlights Gerresheimer's rejection of a takeover bid from Silgan, researchers' progress with CRISPR for Down syndrome, Eli Lilly's obesity pill traction, Trump's push on ...

A compact Cas12f nuclease shows high editing efficiency in human cells, with structural insights enabling an engineered variant potentially suited for future AAV‑compatible delivery.

Banas is associate director of research at the Gene Editing Institute at ChristianaCare, where Kmiec is founder and executive director. The medical promise of CRISPR gene editing can be seen most ...

A research team has discovered an enhanced CRISPR gene-editing system that could enable targeted delivery inside the human ...

Recent commentary has highlighted CRISPR Therapeutics’ expanding gene-editing pipeline, including cardiovascular candidates like CTX310 and CTX320 and programs in type 1 diabetes, alongside fresh Buy ...

In heart failure, the heart can no longer supply the body with enough blood. The condition often develops over many years, ...

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $55.72, moving -1.83% from the previous trading session. The stock trailed the S&P 500, which registered a daily gain of 0.26%. On ...